In support of this hypothesis, the in vitro vasodilatory effects of the sGC activator cinaciguat (but not the NO donor glycerol trinitrate) were potentiated under numerous pathological conditions associated with oxidative stress including atherosclerosis, hypertension, and type 2 diabetes (Stasch et al., 2006). Here, SGCB is linked to type 2 diabetes mellitus.